Protalix BioTherapeutics Inc (PLX) 1.98 USD (+0.01%) | Healthcare New York Stock Exchange

Protalix BioTherapeutics is a biopharmaceutical company specializing in the design of protein treatments derived from plant cells for rare diseases.

biotechnology medical-research

Price history of Protalix BioTherapeutics Inc

Performance & Momentum

6 Months 14.86 %

1 Year 25.62 %

3 Years 11.45 %

5 Years 6.07 %

Momentum

Unlock this indicator

Protalix BioTherapeutics Strengthens Clinical Progress, Partnerships

Protalix BioTherapeutics (NYSE: PLX) recently announced a collaboration with Secarna Pharmaceuticals to develop new antisense oligonucleotide therapies targeting rare kidney diseases. This partnership enhances its innovative biopharmaceutical portfolio addressing unmet medical needs. Despite a slight revenue decline in Q3 2025, the company maintains a strong cash position and continues regulatory and clinical efforts, including a request for CHMP opinion reexamination. These developments indicate a positive medium-term outlook for Protalix.

anantys.com • biotechnology, collaboration, innovation

Strategic Analysis

Protalix BioTherapeutics Inc • 2026

Protalix BioTherapeutics positions itself as a niche biopharmaceutical company focused on the design and commercialization of recombinant therapeutic proteins. Its differentiating factor lies in its plant-based production platform, which enables it to stand out in a highly competitive biotech universe through an original and targeted technological approach.

Strengths

Proprietary production technology based on a differentiated plant-based platform
Niche positioning in high medical value recombinant therapeutic proteins
More constructive recent stock profile, with a renewed level of relative market interest

Weaknesses

Long-term performance track record still fragile, indicating irregular value creation
High dependence on the clinical, regulatory, and commercial success of specific programs

Momentum

Momentum appears favorable and significantly improved, reflecting a more constructive stock-market trend in the short and medium term. For investors, this suggests renewed attention on the story, but still within the speculative framework typical of biotech small caps, where fundamental visibility remains tied to development and commercialization progress.

Analysis performed 3 days ago